Jan Ernest

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz et al. · The Lancet · 2023 · 372 citations

Ocular Disease, Ophthalmology, Age-related Diseases +4

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

Arshad M. Khanani, Sunil Patel, Giovanni Staurenghi et al. · The Lancet · 2023 · 263 citations · Full text

Clinical Epidemiology, Clinical Trials, Geographic Atrophy +5

Faricimab Treat-and-Extend for Diabetic Macular Edema

Tien Yin Wong, Zdenka Hašková, Kemal Asik et al. · Ophthalmology · 2023 · 105 citations · Full text

Faricimab Treat-and-extend, Diabetic Retinopathy, Ocular Disease +3

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

David M. Brown, David S. Boyer, V. Diana et al. · The Lancet · 2024 · 78 citations

Diabetic Retinopathy, Ocular Disease, Ophthalmology +5

Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration

Se Joon Woo, Miroslav Veith, Jan Hamouz et al. · JAMA Ophthalmology · 2020 · 75 citations · Full text